Renal Denervation Devices Market - Global Forecast to 2026, by Product Type (Simplicity Renal Denervation System, Vessix Renal denervation System, EnligHTN, Paradise Renal Denervation System, Iberis Renal sympathetic Denervation System, and Others), by Technology (Radiofrequency and Ultrasound), by End user (Hospitals, Ambulatory Surgical Centers, Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Renal denervation devices is an advanced device used in the treatment of hypertension. Basically, it is a catheter-based therapy in which catheters is inserted into the renal artery to delivers radio-frequency energy in order to ablate the nerves in the vessel wall that control vasoconstriction. This opens the vessels permanently to facilitate greater blood flow to the kidneys.

The global renal denervation devices market size was valued at US$ 88.6 million in 2017 and is expected to exhibit a CAGR of 35.5% over the forecast period (2018 – 2026).

Rising prevalence of hypertension is projected to propel the growth of the renal denervation devices market

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/renal-denervation-devices-market-798

Increasing prevalence of cardiovascular diseases (CVDs) and hypertension is projected to fuel demand for renal denervation devices around the globe. For instance, according to the World Health Organization (WHO), the prevalence of hypertension in adults aged 25 and above was around 40% in 2008 worldwide. According to the American College of Cardiology (ACC)/the American Heart Association (AHA), the clinical practice guidelines of hypertension have modified the definition of hypertension, which has increased the prevalence of hypertension to 45.6% or around 103.3 million people in the U.S. in 2017.

Furthermore, according to WHO 2017, Africa accounts for the highest number of high blood pressure cases worldwide, affecting around 46% of adults, due to increasing urbanization and unhealthy lifestyles. According to the Blood Pressure Association in the U.K., the highest number of people suffering from high blood pressure was recorded in South Asia and parts of Africa, where over 50% of those with high blood pressure lived in the Asia Pacific, including 226 million people in China and 199 million in India in 2015. Therefore, a growing number of high blood pressure cases are projected to boost the market growth.

On the flip side, rising adoption of pharmaceutical therapy for the management of hypertension is expected to restrict the adoption of renal denervation devices, hence hindering the market growth. For instance, according to the American College of Cardiology (ACC)/American Heart Association (AHA), the number of people adopting pharmaceutical therapy increased by 13.9 million (from 24.0 in 2013 % to 54.4% of the treated patients) in the U.S. in 2017. Moreover, around 30 million people in China choose pharmaceutical treatment for hypertension in 2017.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/798

The rising number of research and development activities and regulatory approvals in Europe is projected to bolster the market growth

Europe holds a dominant position in the global renal denervation device market, and this can be attributed to rising research and development activities and regulatory approvals. For instance, in February 2014, Cordis Corporation, a division of Johnson & Johnson, received CE Mark for Renlane renal denervation system. The system consists of a unique, helical shaped, irrigated, a multi-electrode ablation catheter with a multi-channel radiofrequency (RF) ablation system.

Moreover, a growing number of clinical trials on renal denervation devices is also projected to boost market growth. For instance, multi-center, international, single-blind, randomized, sham-controlled clinical trials of RADIANCE-HTN SOLO were conducted at 21 centers in the U.S. and 18 in Europe. The trials meet primary efficacy endpoints, according to an announcement by ReCor Medical in May 2018.

Key Players
Major players operating in the global renal denervation device market include St. Jude Medical, Inc., ReCor Medical Inc., Boston Scientific Corporation, Cardiosonic Ltd, Medtronic Plc., Kona Medical, Inc., Mercator Medsystems, Inc., Terumo Corporation, Abbott Laboratories, and Theragenics Corporation.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/798

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737